CompetitionRisks include lower than projected growth of telehealth revenue, inability to acquire and retain new patients, and higher than expected competition.
FDA Ruling ImpactThe FDA ruling that Novo Nordisk's injectable semaglutide is no longer in shortage led to a significant decline in LFMD shares.
Patient Conversion ChallengeLFMD must convert its patients from compounded semaglutide to branded alternatives within 90 days, posing a challenge.